A Retrospective Study of the Real-Life Utilization and Effectiveness of Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration In the UK

Clinical Ophthalmology - New Zealand
doi 10.2147/opth.s92627
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Informa UK Limited

Related search

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Cohort Study for the UK.

Health Technology Assessment
MedicineHealth Policy
2012English

Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)

BMC Geriatrics
GerontologyGeriatrics
2010English

Profile of Conbercept in the Treatment Of neovascular Age-Related Macular Degeneration

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2015English

Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up

Clinical Ophthalmology
Ophthalmology
2016English

Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment

Journal of Clinical & Experimental Ophthalmology
2012English

Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration

European Ophthalmic Review
2012English

Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration

Ophthalmology
Ophthalmology
2014English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy